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Abstract 
Introduction: Maternal vaccination is increasingly part of antenatal care in the UK and 
worldwide. Trials of Group B streptococcus (GBS) vaccines are ongoing. This study 
investigated the attitudes of pregnant women and healthcare professionals towards antenatal 
vaccination, both in routine care and a clinical trial setting. Material and methods: Survey of 
269 pregnant women, 273 midwives/obstetricians and 97 neonatal doctors across seven sites 
in the UK assessing attitudes towards antenatal vaccinations, knowledge of GBS, a 
hypothetical GBS vaccine and participation in clinical vaccine trials. Results: Sixty-eight 
percent of pregnant women intended to receive a vaccine during their current pregnancy 
(183/269) and 43% (of all respondents, 115/269) reported they would be very/fairly likely to 
accept a vaccine against GBS despite only 29% (55/269) knowing what GBS was. This 
increased to 69% after additional information about GBS was provided. Twenty-four percent 
of pregnant women reported they would be likely to take part in a clinical trial of an 
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unlicensed GBS vaccine. Fifty-nine percent of maternity professionals and 74% of 
neonatologists would be likely to recommend participation in a GBS vaccine trial to women, 
with the vast majority (>99%) willing to be involved in such a study. Incentives to take part 
cited by pregnant women included extra antenatal scans and the opportunity to be tested for 
GBS. Conclusion: Pregnant women and healthcare professionals were open to the idea of an 
antenatal GBS vaccine and involvement in clinical trials of such a vaccine. Education and 
support from midwives would be key to successful implementation. 
 
Keywords 
Group B streptococcus, antenatal vaccine, pregnancy, attitudes, healthcare professionals, 
pregnant women, clinical trials 
 
Abbreviations 
GBS- Group B streptococcus 
 
Key Message 
Both pregnant women and healthcare professionals were open to the idea of an antenatal 
Group B streptococcus vaccine and involvement in clinical trials of such a vaccine. Education 
and support from midwives would be key to successful implementation. 
 
Introduction 
Immunisation of pregnant women to protect both themselves and/or their infants is 
increasingly part of routine care both in the UK and worldwide. Current UK 
recommendations state that all pregnant women should receive a pertussis-containing vaccine 
from 16 to 32 weeks gestation and the influenza vaccine during the influenza season, at any 
stage of gestation (1, 2). There is evidence that these antenatal vaccines are both safe, and 
effective at preventing disease both in the mother and the infant (3-7).  
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Around 60-75% of UK pregnant women received the pertussis vaccine in 2016 (8), with a 
marked increase between winter 2015 and 2016 (8). However, uptake rates for influenza 
remain sub-optimal with recent figures showing that only 43% of eligible pregnant women 
received the influenza vaccine in 2016 (9); thus a significant proportion of pregnant women 
and their babies remain susceptible to potentially fatal, yet preventable, diseases. 
Antenatal immunisation also offers the potential to target additional major neonatal 
pathogens including Group B streptococcus (GBS), the leading cause of sepsis and 
meningitis in infants under the age of 3 months (10, 11). There was around 850 cases 
(0.95/1000 live births) of culture-proven confirmed GBS cases in the UK and Republic of 
Ireland in the 13 months from April 2014 resulting in 53 deaths (personal communication, 
unpublished data C. O’Sullivan), substantially more than the 14 deaths from neonatal 
pertussis infections in the 2012 pertussis outbreak that prompted the current maternal 
immunisation strategy (12). Strategies for the prevention of neonatal GBS infection include 
the risk-based intrapartum antibiotic approach currently used in the UK (13), or a universal 
swab-based screening programme used in the USA, Canada, much of Europe and parts of 
Australia (14, 15). Neither strategy impacts on GBS disease beyond the first week of life, and 
both have the potential to miss cases or contribute to the overuse of antibiotics. An antenatal 
vaccine against GBS is therefore desirable and clinical trials of candidate GBS vaccines 
involving over 500 pregnant women have been conducted (16) or are ongoing (17).  
The aim of this study was to investigate the attitudes of pregnant women and the healthcare 
professionals involved in their care, towards antenatal vaccination, GBS disease and the 
prospect of a GBS vaccine. Secondary aims included identifying factors affecting vaccine 
uptake and exploring attitudes towards participating in clinical trials of an antenatal GBS 
vaccine, and how these could be addressed to optimise uptake in a routine setting and in 
recruitment for clinical trials.  
 
Material and methods 
Self-completed paper questionnaires in English were distributed to 356 pregnant women, 407 
maternity professionals (defined as practising midwives or doctors working in obstetric 
practice) and 118 neonatal doctors across seven NHS trusts in the UK. The sites were Oxford 
University Hospitals NHS Foundation Trust, NHS Lothian in Edinburgh, Imperial College 
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Healthcare NHS Trust and St George’s University Hospitals NHS Foundation Trust in 
London, University Hospital Southampton NHS Foundation Trust, University Hospitals 
Bristol NHS Foundation Trust and Central Manchester University Hospitals and NHS 
Foundation Trust. Pregnant women were recruited from October 2014 until June 2015, and 
healthcare professionals from October 2014 until July 2015.  
Three different questionnaires were developed for each of the groups of interest (Supporting 
Information Appendix S1). Inclusion criteria were that the respondent should be over 18, be 
able to read and write English and be either pregnant or working as a midwife (including 
community midwives), obstetric doctor or neonatal doctor at one of the study sites.  
The questionnaires were developed after reviewing the literature, using data collected from 
an online survey of over one thousand women of child bearing age (18), and in-depth 
qualitative work with pregnant women, parents with experience of GBS and maternity 
professionals (19). Prior to the national survey, the questionnaires were piloted amongst the 
interview and focus group participants and adapted based on their feedback.  
Questionnaires were distributed by study staff in antenatal clinic waiting rooms, antenatal 
classes, multi-professional meetings, staff rooms and via email. Participation was voluntary, 
the questionnaires were confidential, anonymous and no personal identifying information was 
collected. Respondents were asked to tick a box at the beginning of the questionnaire to 
indicate that they understood their answers would be used as part of a research study. 
Respondents were also given a sealed envelope with the GBS additional information sheet 
(Supporting Information Appendix S2) which they were instructed to open at a specified 
point. 
 
Statistical analyses 
Questionnaires were returned to a single site (Oxford) and data entered into the OpenClinca 
database before being exported to the Microsoft Excel software program for analysis. 
Statistical analyses were conducted with Graphpad Prism software (GraphPad, La Jolla, 
USA)  using Chi-square and Fisher’s exact tests. Not all questions were fully completed by 
every respondent, however, unless otherwise stated, the percentages stated are of all 
responses with those who did not complete the question recorded as missing data. For the 
ranking questions, data were included even if the respondents only ranked some of the 
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options. However if the respondent only ticked, rather than numbered, boxes, this were 
recorded as “uninterpretable” and counted as missing data. 
Ethical approval 
The study was approved by the NRES Committee South Central- Hampshire A ethics 
committee reference 13/SC/0619. The study was funded by a grant from the charity 
Meningitis Now.  
 
Results  
A total of 356 pregnant women, 407 maternity professionals and 118 neonatal doctors were 
approached to take part in the study and 300 (84.3%), 306 (75.2%) and 101 (85.6%) 
completed the questionnaire, respectively. Of these, 31 pregnant women, 33 maternity 
professionals and 4 neonatal doctors were excluded from the final analysis as they had not 
ticked the ‘permission’ box, leaving 269 pregnant women, 273 maternity professionals and 
97 neonatal doctors.  
The age of the pregnant women ranged from eighteen to forty-six years and ethnicity was 
well matched for the UK population (20). Further demographic details for all groups are 
shown in Tables 1 and 2.  
Seventy-seven percent (208/269) of the pregnant women recollected being offered at least 
one vaccination during their current pregnancy (Table 1) and 68% (of all respondents, 
182/269) indicated that they had received or intended to receive a vaccination during this 
pregnancy, 19.7% (53/269) did not intend to have any vaccinations and 11.2% (30/269) were 
undecided. Vaccination details for the healthcare professionals are shown in Table 1. When 
pregnant women were asked to rank the relative importance of the potential benefits of 
antenatal vaccination, the highest ranking was protecting their baby from a rare but serious 
condition, while protecting self or others was less important (figure 1). Major concerns about 
receiving antenatal vaccination were that it might cause harm to the baby and specifically that 
it may cause a miscarriage (figure 2). Factors influencing whether the maternity professionals 
would recommend a vaccine in pregnancy also highlighted the perceived importance of 
preventing serious conditions as 24.2% (66) ranked this as the most important consideration. 
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The existence of a national recommendation was also key with 32.2% (88) of maternity 
professionals stating this was the factor which would be most influential.   
Pregnant women reported receiving information about antenatal immunisation from their 
midwife, obstetrician or general practitioner (187, 69.5%), via leaflets (132, 49.1%) or their 
own independent research (46, 17%, multiple answers permitted). However, 18% (49) 
reported they had received no information about antenatal vaccination; these women were 
significantly less likely to have had, or to intend to have, any antenatal vaccines than those 
who had received information (table 2).  
Forty-six percent (124) stated that the most important source of information would be their 
midwife, with general practitioners and obstetricians being the next most highly-ranked 
sources and the media being least popular. Those who had a discussion with their midwife, 
general practitioner or obstetrician (as opposed to only a leaflet/own research) were more 
likely to have/to intend to have, a vaccine (table 2). Ninety-four percent (258) of maternity 
professionals agreed that information about vaccination in pregnancy was most appropriately 
delivered by midwives.  
Neither age nor having other children appeared to significantly affect the decision to have an 
antenatal vaccination, although White British respondents were significantly more likely to 
have had/to intend to have vaccination than those identifying themselves as Black or White 
Other, the majority of whom were from elsewhere in Europe (table 2).  
Both maternity professionals and pregnant women considered 21-30 weeks’ gestation to be 
the most acceptable time in pregnancy for vaccination (pregnant women: 21.2% (57), 
maternity professionals: 40.7% (111)). Themes emerging from the free text answers for both 
groups included a perception that this was a “safer” time as the baby was more developed and 
there was less risk of miscarriage. 
Knowledge about GBS amongst pregnant women was low with 70% (189) reporting that they 
didn’t know what it was (figure 3). Almost all the maternity professionals (269, 98.5%) and 
neonatal doctors (96, 99%) had some clinical experience of GBS, with similar percentages in 
both groups reporting they had had discussions with women about GBS (pre or post-natal) or 
prescribed/administered antibiotics for GBS. Most (94.8%, 92) of neonatal doctors had 
experience of caring for a baby with GBS infection compared to 61.5% (168) of maternity 
professionals. Preferred preventive strategies for GBS also varied between the healthcare 
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professional groups with universal screening of all pregnant women preferred by maternity 
professionals (116, 42.5%, more than one response permitted) and vaccination by the 
neonatal doctors (48, 49.5%). Only 32.2% (88) and 24.7% (24) respectively felt the current 
UK risk based approach was most appropriate. 
Before and after reading a leaflet with information about GBS, all respondents were asked 
how likely they would be to either have (pregnant women), recommend (maternity 
professionals) or support (neonatal doctors) a GBS vaccine. Prior to reading the information, 
42.8% (115) of pregnant women stated they would be very/fairly likely to receive the 
vaccine, which rose to 68.4% (184) after reading the information (figure 4a). The shift was 
less dramatic for maternity professionals (figure 4b) and there was virtually no change for 
neonatal doctors (figure 4c).  
Respondents were asked whether they would accept, recommend or support a GBS vaccine 
according to different numbers of previous vaccine recipients in clinical trials (figure 5). The 
percentage of pregnant women willing to accept the vaccine increased from 30% to 60% as 
the hypothetical number of previous recipients increased from 1,000 to 10,000. The most 
frequently cited period of required follow up for adverse outcomes before maternity 
professionals or neonatal doctors would recommend the vaccine was 5 years (133 (48.7%) 
and 55 (56.7%), respectively).  
After reading additional information about the current trial status of GBS vaccines, 23.8% 
(64) of pregnant women stated that they would be very or fairly likely to take part in a 
clinical trial of a GBS vaccine. This was not significantly affected by age, parity, or ethnicity. 
The most frequently preferred mode of recruitment was to be invited by their own midwife 
(49.8%, 134). Internet adverts, for example, on parent forums or emails from the study team 
were not popular. When the concept of a randomised control trial was explained (i.e. that they 
may or may not receive the active vaccine and would not be able to choose), the majority of 
women (177, 65.8%) felt this would not affect their decision to take part, however 4.5% (12) 
would be more likely to take part as there was a chance they would not get the vaccine (but 
still receive the benefits of being in the trial) and 12.6% (34) would be less likely to take part 
as they would want a guarantee of receiving the vaccine. 
Healthcare professionals were generally supportive of GBS vaccine trials with 59.3% (162) 
of maternity professionals and 74.2% (72) of neonatal doctors very or fairly likely to 
recommend a pregnant woman to take part in a trial. Almost all (>99%) wanted to be 
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involved in some capacity if their hospital was taking part in a GBS trial, with 78% (213) of 
maternity professionals willing to discuss the trial, 42% (113) to take consent, and 30.5% 
(82) to administer the vaccine. Neonatal doctors were also keen to be involved with 46.4% 
(45) willing to be part of the study team and 41.2% (40) to take consent. 
Among the pregnant women, strong motivators which would make respondents more likely 
to take part in a clinical trial included having extra scans, being tested themselves for GBS 
carriage, their baby having regular check-ups for several years and having extra antenatal 
appointments (Figure 6).  
“I think it's great that a vaccine is being tried and tested to develop into something which can 
save lives and limit effects of GBS.” 
Pregnant woman SP032 
“For me to take part in the trial, I would need time to think about it, real info on the possible 
risks and benefits to myself, my baby and others.  All discussed with my midwife, so it is 
face to face.” 
Pregnant woman OP030 
Concerns expressed in the free text section centred on any risk to the baby, particularly of 
miscarriage,  
“Risk of miscarriage or other health complications for the baby in utero and beyond. I would 
be more likely to take part in research concerning my health alone and not that of an unborn 
child, who has no choice.” 
Pregnant woman SP003 
The potential, unknown, long-term side effects were also a concern and that some women 
disliked the thought of being a “guinea pig”.  
In a similar way, maternity professionals and neonatal doctors were concerned about the 
potential risks to both mother and baby, though the prospect of litigation if things went wrong 
ranked as the third highest concern and extra workload was also a potential issue. 
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Discussion 
This study provides important new insights on the attitudes of pregnant women and 
healthcare professionals towards antenatal vaccination and clinical vaccine trials involving 
pregnant women in the UK. Other attitudinal studies have been conducted mainly in the USA 
(21), or have focused on single vaccines (22) and few have assessed the views of healthcare 
professionals (23), or considered clinical trial participation.   
Our findings suggest that provision of information is key to encourage antenatal vaccine 
uptake. However a significant number of women reported they had not been offered 
information and fears persist about the perceived risk of miscarriage or harm to the baby. 
Similar concerns have been highlighted in other studies exploring attitudes to maternal 
immunisation, among different populations such as in the USA and Australia (21, 22, 24). 
Our data suggest that emphasising the protection for the baby and the potential severity of the 
infections, rather than benefit for mother or protection from a common illness could be more 
effective at promoting vaccine uptake. This may partly explain the difference in uptake 
between the pertussis and influenza vaccines as pertussis is primarily presented as protecting 
the baby while influenza vaccine programmes are primarily designed to protect the pregnant 
women herself, despite evidence that they can also improve the health of babies (3). 
Differences in the perception of the severity of pertussis and influenza for mother and infant 
have been reported elsewhere, with influenza generally not regarded as serious by any group 
(25).  However other factors, such as the different gestation at which these vaccines are 
recommended, may also play a part.  
It is vital that healthcare professionals are aware of the evidence regarding the safety of 
antenatal vaccination, in particular that there appear to be no increased risks and that there 
may be additional benefits (3, 6, 7, 26), such as improved birthweight. Providing a short, 
written information sheet can be very effective as demonstrated by the 26% increase in 
pregnant women likely to accept a GBS vaccine after reading the information sheet, although 
for the women surveyed here, discussion with a healthcare professional significantly 
increased the likelihood of acceptance compared to written information alone. As well as 
having knowledge, maternity professionals need training about how best to communicate key 
information to all pregnant women. Shortly after the introduction of the antenatal influenza 
vaccine, Ishola et al found that only 26% of London midwives felt well prepared to advise 
women about the influenza vaccine (27). Evidently this is an important area for development. 
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The specific concern about miscarriage, now of particular relevance to both the influenza and 
pertussis vaccines which may be given early in pregnancy, should be actively addressed and 
reassurance given.  
The low level of awareness among pregnant women about GBS is consistent with other UK 
studies (18) and is perhaps unsurprising in the UK context where screening for GBS is not 
routine (13). However this could have important implications for the uptake of a future GBS 
vaccine and our data suggest that implementation will need to be accompanied by an 
intensive education campaign for both pregnant women and maternity professionals. One 
other study in the USA, exploring the attitudes of pregnant women towards a hypothetical 
GBS vaccine, reported a higher potential acceptance rate of 79% (28) although it is important 
to note that this was in the context of a routine GBS screening programme. 
The data regarding  pregnant women’s’ potential involvement in a clinical trial are novel and 
are  of practical relevance for those designing and recruiting to studies of antenatal vaccines 
including not only those against GBS but also other major pathogens such as Respiratory 
Syncytial Virus. Encouragingly, almost a quarter of pregnant women would consider taking 
part in a hypothetical GBS clinical trial and healthcare professionals were also supportive in 
that they would be willing to provide significant practical help to the study teams. The 
involvement of the patient’s own clinician is particularly important in optimising 
participation (29), although our previous qualitative work has suggested that some maternity 
professionals may be very ambivalent about clinical vaccine trials (19). It is reassuring that 
these were not the views of this more representative sample of UK maternity professionals 
and suggests that recruiting local staff to be part of the study team could be key to success. 
While maternity professionals have the most contact with pregnant women, neonatal doctors 
could also prove to be a valuable resource as a group which strongly supports antenatal 
vaccination and could be involved in long-term postnatal follow up, an important motivator 
for the pregnant women. Contrary to the usual emphasis on minimising the number of visits 
to cause as little inconvenience as possible in many standard vaccine studies, it seems that 
offering additional time, scans and appointments could improve the likelihood of pregnant 
women participating, while incentives such as vouchers or money would have little effect on 
recruitment. A previous study of mostly non-pregnant women had indicated that those with 
children might be more likely to take part in a clinical vaccine trial (30), although the 
differences here were not significant. In the same study among non-pregnant women, 32% of 
respondents indicated they would be very/fairly likely to take part (18) compared to 23.8% of 
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the pregnant women surveyed here. However, for women who are pregnant, the scenario of 
engaging in a vaccine study while pregnant is closer to their current situation and the results 
shown here are more likely to reflect reality. 
There are a number of limitations to this study to be acknowledged. Only respondents who 
could read and write English were included, thus we excluded important groups who are 
likely to have particular challenges in accessing information and the vaccines themselves. 
Future work should make special efforts to reach this under-represented population. While 
the ethnic background of our sample was proportionally representative of the UK population, 
there were relatively few respondents from ethnic minorities and ethnicity is known to 
influence attitudes towards healthcare and vaccination (21, 22). Similarly, there should be 
caution in extrapolating these data to populations where screening for GBS is routine in 
whom background knowledge of GBS among pregnant women may be greater. Though a 
high proportion of those approached (75-85%) agreed to take part in the study, no data were 
collected on those who declined to participate and although a broad range of ages, gestations 
and parity were included, we cannot rule out responder bias. Only vaccine trials and real life 
implementation will confirm whether the interventions suggested by these data are able 
increase vaccine uptake. 
 
Antenatal vaccination is an important tool with increasing potential to reduce both maternal 
and neonatal mortality and morbidity, if it can be delivered effectively. In keeping with 
previous studies, these data show that both pregnant women and the healthcare professionals 
do have concerns about the use of vaccination in pregnancy, but encouragingly many are 
open to the concept of novel vaccines and willing to participate in research to bring these 
forward. Education of both pregnant women and those caring for them is key to both improve 
uptake of current and future vaccines and help optimise recruitment for clinical trials to 
further reduce the burden of neonatal disease both in the UK and worldwide.  
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Supporting Information legends 
Appendix S1: Survey questions for pregnant women, maternity professionals and neonatal 
doctors. 
Appendix S2: GBS fact sheet. 
 
Table and figure legends 
Table 1 Participant demographic details (percentages rounded to one decimal place). 
 
Table 2 Had/intend to have antenatal vaccination according to whether information received 
and ethnicity. 
 
Figure 1: Pregnant women, perceived benefits of antenatal vaccination. 1 = most important, 7 
= least important (n= number of respondents giving that rank to any statement). 
 
Figure 2: Pregnant women, concerns about antenatal vaccines. 1= greatest concern, 10 = least 
(n= number of respondents giving that rank to any statement). 
 
Figure 3: Pregnant women, “Have you heard of group B streptococcus (sometimes called 
Group B strep or GBS)?” Of the 22 (8%) women who reported being directly affected by 
GBS, 2 indicated having a previous child with GBS infection, 11 a positive GBS swab in this 
or a previous pregnancy, 6 knew a friend/family who had a child with GBS infection, 1 
reported that she had had GBS, 1 that a friend had been told her recurrent miscarriages could 
be due to GBS and another did not specify. 
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Figure 4: a) Pregnant women, b) maternity professionals and c) neonatal doctors, likelihood 
of receiving/recommending/supporting an antenatal vaccination against GBS before and after 
reading information sheet. 
 
Figure 5: Number of pregnant women who would have to have had the vaccine before each 
group would consider receiving, recommending or supporting a GBS vaccine. 
 
Figure 6: Pregnant women, motivators to take part in a GBS vaccine trial. 1 = most preferred, 
9 = least preferred. (n= number of respondents giving that rank to any statement). 20% (54) 
stated that nothing would make them more likely to take part. 
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Pregnant women 
 
 
 
 
Site 
Oxford 31/11.5% 
28/10.4% 
24/8.9% 
39/14.5% 
29/10.8% 
88/31.7% 
30/11.2% 
St George’s, London 
Imperial, London 
Southampton 
Manchester 
Bristol 
Edinburgh 
 
 
Age (years) 
18-24 34/12.6% 
96/35.7% 
88/32.7% 
36/13.4% 
13/4.8% 
1/0.4% 
1/0.4% 
25-30 
31-35 
36-40 
41-45 
 46+ 
 Missing data 
 
 
Ethnicity 
White British 192/71.4% 
14/5.2% 
22/8.2% 
9/3.3% 
26/9.7% 
1/0.4% 
5/1.9% 
Black 
Middle East and Asia 
Mixed/multiple ethnicity 
White other (mainly 
European) 
Other 
Prefer not to say/missing 
data 
 
 
Gestation 
(weeks) 
Less than 12 20/7.4% 
67/24.9% 
53/19.7% 
56/20.8% 
12-16 
17-20 
21-30 
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31-36 41/15.2% 
30/11.2% 
2/0.7% 
37+ 
 Missing data 
 
 
 
Number of 
children 
0 120/44.6% 
90/33.5% 
40/14.9% 
9/3.3% 
7/2.6% 
1/0.4% 
1/0.4% 
1/0.4% 
1 
2 
3 
4 
5 
6 
7 
 
Have you 
been offered 
any antenatal 
vaccinations? 
Yes-overall 208/77.3% 
124/46.0% 
187/69.5% 
57/21.2% 
4/1.5% 
Yes- Pertussis
a
 
Yes- Influenza 
No 
Don’t know 
 
Healthcare professionals 
 
 Maternity professionals 
(number/percentage) 
Neonatal Doctors 
(number/percentage) 
 
 
 
Profession 
Midwife 189/68.1% N/A 
Consultant grade doctor 28/10.3% 30/30.9% 
Pre-consultant grade 
doctor 
52/19.0% 56/57.7% 
Doctor (other) 1/0.4% 11/11.3% 
Advanced neonatal nurse 
practitioner 
N/A 1/1.0% 
Maternity research nurse 1/0.4% N/A 
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Missing data 2/0.7% 0 
 
 
Years of 
clinical 
practice 
0-5 86/31.5%  
 
 
Not recorded 
6-10 54/19.8% 
11-15 46/16.8% 
16-20 28/9.9% 
21-25 24/8.8% 
25+ 33/12.1% 
Missing data 2/0.7% 
Have you 
been offered 
any vaccines 
in the last 
year?
b
 
Yes 216/79.1% 64/66.0% 
No 57/30.9% 33/34.0% 
 
Have you 
had any 
vaccines in 
the last 
year?
a
 
Yes 142/52.0% 64/66.0% 
No (but offered) 70/35.6% 0 
Missing data 4/1.5% 0 
Not applicable (not 
offered) 
57/30.9% 33/34.0% 
Do you 
recommend 
both 
influenza and 
pertussis 
vaccines to 
pregnant 
women? 
Yes 226/82.8%  
N/A No
c
 41/15.0% 
Missing data 6/2.2% 
 
Table 1: Participant demographic details (percentages rounded to one decimal place). 
aAt the time of this survey, pertussis vaccination was recommended to be given at around 28-32 weeks. If only 
those over 21 weeks gestation were included, the percentage who recalled being offered pertussis vaccine rose 
to 68.3%. 
bNational policy in the UK recommends that all healthcare professionals should receive annual influenza 
vaccination. 
cSome qualified this with a statement that vaccine recommendations do not fall into their clinical practice. 
Sixteen recommended either pertussis or influenza but not both. 
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Table 2: Had/intend to have antenatal vaccination according to whether information received 
and ethnicity. 
 Yes Don’t know No Missing data p value 
 
Received 
Information (n=201) 
 
 
75.6% 
(152) 
 
8.0% (16) 
 
14.9% (30) 
 
1.5% (3) 
 
    
 
<0.0001 
 
No information 
(n=49) 
 
 
36.7% (18) 
 
22.4% (11) 
 
40.8% (20) 
 
0 (0) 
Note: Nineteen respondents did not answer whether they had received information and are not included above 
 
Of those who reported receiving information: 
 
 
Information direct 
from Professional  
 
 
79.4% 
(123) 
 
7.7% (12) 
 
11.0% (17) 
 
1.9% (3) 
 
 
 
0.0257 
Written 
information/own 
research only 
 
63.0% (29) 
 
8.7%(4) 
 
23.2% (13) 
 
0 (0) 
 
Ethnicity 
p value 
(comparison 
with White 
British) 
 
White British 
 
 
72.9% 
(140) 
 
13.0% (25) 
 
13.0% (25) 
 
1.0% (2) 
- 
 
Black 
 
 
42.9% (6) 
 
7.1% (1) 
 
42.9% (6) 
 
7.1% (1) 
 
0.0045 
 
Middle East/Asia 
 
59.1% (13) 
 
9.1% (2) 
 
31.8% (7) 
 
0 (0) 
 
NS 
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Mixed 
 
 
66.7% (6) 
 
22.2% (2) 
 
11.1% (1) 
 
0 (0) 
 
NS 
 
White other 
 
 
53.8% (14) 
 
0 (0) 
 
42.3% (11) 
 
3.8% (1) 
 
0.0005 
 
Other 
 
 
100% (1) 
 
0 (0) 
 
0 (0) 
 
0 (0) 
 
NS 
Prefer not to 
say/Missing Data 
 
 
40% (2) 
 
0 (0) 
 
60% (3) 
 
0 (0) 
 
0.0293 
 
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
 
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
 
 
 
 
 
 
